Strong infiltration of immune cells in HER-2 amplified breast tumors augments the response to HER2-targeted agents such as trastuzumab and pertuzumab, thus, prompting tumor cell death by means of antibody-dependent cellular cytotoxicity mechanism (59). The gene discussed is ERBB2; the disease is breast neoplasm.